Literature DB >> 21335512

Competing-risk analysis of ESRD and death among patients with type 1 diabetes and macroalbuminuria.

Carol Forsblom1, Valma Harjutsalo, Lena M Thorn, Johan Wadén, Nina Tolonen, Markku Saraheimo, Daniel Gordin, John L Moran, Merlin C Thomas, Per-Henrik Groop.   

Abstract

Patients with both type 1 diabetes and CKD have an increased risk of adverse outcomes. The competing risks of death and ESRD may confound the estimates of risk for each outcome. Here, we sought to determine the major predictors of the cumulative incidence of ESRD and pre-ESRD mortality in patients with type 1 diabetes and macroalbuminuria while incorporating the competing risk for the alternate outcome into a Fine-Gray competing-risks analysis. We followed 592 patients with macroalbuminuria for a median of 9.9 years. During this time, 56 (9.5%) patients died and 210 (35.5%) patients developed ESRD. Predictors of incident ESRD, taking baseline renal function and the competing risk for death into account, included an elevated HbA(1c), elevated LDL cholesterol, male sex, weight-adjusted insulin dose, and a shorter duration of diabetes. By contrast, predictors of pre-ESRD death, taking baseline renal function and the competing risk for ESRD into account, included only age, the presence of established macrovascular disease, and elevated cholesterol levels. This competing-risks approach has potential to highlight the appropriate targets and strategies for preventing premature mortality in patients with type 1 diabetes.

Entities:  

Mesh:

Year:  2011        PMID: 21335512      PMCID: PMC3060447          DOI: 10.1681/ASN.2010020194

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  24 in total

Review 1.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.

Authors:  T A Gooley; W Leisenring; J Crowley; B E Storer
Journal:  Stat Med       Date:  1999-03-30       Impact factor: 2.373

2.  Long-term predictors of coronary artery disease and mortality in type 1 diabetes.

Authors:  U Weis; B Turner; J Gibney; G F Watts; V Burke; K M Shaw; M H Cummings
Journal:  QJM       Date:  2001-11

3.  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

Authors: 
Journal:  Am J Kidney Dis       Date:  2002-02       Impact factor: 8.860

4.  Risk for ESRD in type 1 diabetes remains high despite renoprotection.

Authors:  Elizabeth T Rosolowsky; Jan Skupien; Adam M Smiles; Monika Niewczas; Bijan Roshan; Robert Stanton; John H Eckfeldt; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2011-02-25       Impact factor: 10.121

5.  Comparison of 2 methods for calculating adjusted survival curves from proportional hazards models.

Authors:  W A Ghali; H Quan; R Brant; G van Melle; C M Norris; P D Faris; P D Galbraith; M L Knudtson
Journal:  JAMA       Date:  2001-09-26       Impact factor: 56.272

6.  Endothelial vasodilator function is related to low-density lipoprotein particle size and low-density lipoprotein vitamin E content in type 1 diabetes.

Authors:  R A Skyrme-Jones; R C O'Brien; M Luo; I T Meredith
Journal:  J Am Coll Cardiol       Date:  2000-02       Impact factor: 24.094

7.  Predictors of mortality and end-stage diabetic complications in patients with Type 1 diabetes mellitus on intensified insulin therapy.

Authors:  I Mühlhauser; H Overmann; R Bender; V Jörgens; M Berger
Journal:  Diabet Med       Date:  2000-10       Impact factor: 4.359

8.  Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  Trevor J Orchard; Jon C Olson; John R Erbey; Katherine Williams; Kimberly Y-Z Forrest; Leslie Smithline Kinder; Demetrius Ellis; Dorothy J Becker
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

9.  Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study.

Authors:  P Rossing; P Hougaard; K Borch-Johnsen; H H Parving
Journal:  BMJ       Date:  1996-09-28

10.  Hypercholesterolemia--a determinant of renal function loss and deaths in IDDM patients with nephropathy.

Authors:  A S Krolewski; J H Warram; A R Christlieb
Journal:  Kidney Int Suppl       Date:  1994-02       Impact factor: 10.545

View more
  44 in total

Review 1.  Novel biomarkers for the progression of diabetic nephropathy: soluble TNF receptors.

Authors:  Tomohito Gohda; Yasuhiko Tomino
Journal:  Curr Diab Rep       Date:  2013-08       Impact factor: 4.810

2.  Death, end-stage renal disease and renal function decline in patients with diabetic nephropathy in French cohorts of type 1 and type 2 diabetes.

Authors:  Samy Hadjadj; Bertrand Cariou; Frederic Fumeron; Elise Gand; Guillaume Charpentier; Ronan Roussel; Ahmed-Amine Kasmi; Jean-François Gautier; Kammel Mohammedi; Pierre Gourdy; Pierre-Jean Saulnier; Eva Feigerlova; Michel Marre
Journal:  Diabetologia       Date:  2016-01       Impact factor: 10.122

3.  Renal outcomes in patients with type 1 diabetes and macroalbuminuria.

Authors:  Ian H de Boer; Maryam Afkarian; Tessa C Rue; Patricia A Cleary; John M Lachin; Mark E Molitch; Michael W Steffes; Wanjie Sun; Bernard Zinman
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Risk for ESRD in type 1 diabetes remains high despite renoprotection.

Authors:  Elizabeth T Rosolowsky; Jan Skupien; Adam M Smiles; Monika Niewczas; Bijan Roshan; Robert Stanton; John H Eckfeldt; James H Warram; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2011-02-25       Impact factor: 10.121

5.  Improved glycemic control and risk of ESRD in patients with type 1 diabetes and proteinuria.

Authors:  Jan Skupien; James H Warram; Adam Smiles; Andrzej Galecki; Robert C Stanton; Andrzej S Krolewski
Journal:  J Am Soc Nephrol       Date:  2014-06-05       Impact factor: 10.121

6.  Diabetes: Assessing renal risk in patients with type 2 diabetes.

Authors:  Merlin C Thomas; Per-Henrik Groop
Journal:  Nat Rev Nephrol       Date:  2013-09-17       Impact factor: 28.314

7.  The association of parathyroid hormone with ESRD and pre-ESRD mortality in the Kidney Early Evaluation Program.

Authors:  Georges Saab; Andrew S Bomback; Samy I McFarlane; Suying Li; Shu-Cheng Chen; Peter A McCullough; Adam Whaley-Connell
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

8.  High risk of ESRD in type 1 diabetes: new strategies are needed to retard progressive renal function decline.

Authors:  Andrzej S Krolewski; Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

9.  Differential mortality and the excess burden of end-stage renal disease among First Nations people with diabetes mellitus: a competing-risks analysis.

Authors:  Ying Jiang; Nathaniel Osgood; Hyun-Ja Lim; Mary Rose Stang; Roland Dyck
Journal:  CMAJ       Date:  2013-12-02       Impact factor: 8.262

10.  Cilostazol effectively attenuates deterioration of albuminuria in patients with type 2 diabetes: a randomized, placebo-controlled trial.

Authors:  Wen-Hao Tang; Fu-Huang Lin; Chien-Hsing Lee; Feng-Chih Kuo; Chang-Hsun Hsieh; Fone-Ching Hsiao; Yi-Jen Hung
Journal:  Endocrine       Date:  2013-06-18       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.